Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
Abstracts related to the conduct of clinical trials, not the actual trials results, from ASCO can be found under the category Health Services Research. Those are then broken down into four areas--
Following is a list of abstracts submitted to ASCO for either presentation at the event or for online only for topics related to clinical trials.
Access to Children’s Oncology Group Phase I clinical trials: Racial/ethnic dissimilarities in participation
Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG)
Discussions about clinical trials among patients with lung and colorectal cancer
Equity of access: Consent interpretation program at Princess Margaret Cancer Centre (PM) in Canada
Exclusion of patients with prior cancers from clinical trials: Is this justified?
FDA breakthrough therapy designation of oncology products: The first-year experience
Media reporting of practice-changing clinical trials in oncology: A North American perspective
Social media use amongst oncologists: Results of a national physician survey
Why is it so difficult to enroll patients in clinical trials?
Are new drugs more expensive than old ones? Trends in the benefit-adjusted launch prices of anticancer drugs, 1995-2013
Avoided cost in chemotherapy drugs by patient inclusion in clinical trials
Developing a predictive model for cancer clinical trial accrual
How much is the pharmaceutical industry's cost of capital for clinical research of novel drugs?
Hispanic accrual on randomized cancer clinical trials: A call to arms
Impact of prior cancer on eligibility for lung cancer clinical trials
A randomized, controlled study comparing NCI’s original and revised informed consent templates
A tool to help research programs exceed the minimum standards of conducting clinical research
A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
An analysis of cancer-specific Twitter conversations among physicians in 2013
Are manufacturers targeting smaller patient populations and are they being rewarded for it?
Are preclinical research findings replicable: An empirical analysis based on EpoR studies in cancer
Audio visual recording of informed consent: Novel mandatory regulatory compliance for clinical trials in India
Clinical trial subjects compared to "real world" patients: Generalizability of renal cell carcinoma trials
Comparison of results between the first and updated reports of phase III clinical trials (RCTs)
Data quality in clinical trials
Development of a patient preference assessment tool for cancer patients considering phase I research
Development of a patient-reported outcome (PRO) measure for assessing non-small cell lung cancer (NSCLC) symptoms in clinical trials: Interim report from the PRO Consortium’s NSCLC Working Group (WG)
Drug-company–sponsored lectures and physicians' prescribing patterns
Impact of National Cancer Institute (NCI)-mandated scientific review on protocol development and content
Impact of the NCI Community Cancer Centers Program (NCCCP) on clinical trial (CT) activities in a community cancer center in rural Nebraska
Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience
Improving the patient (pt) experience through physician engagement
Mobile solution for clinical research documentation
NCI pilot intervention program to assist accrual for challenging late-phase clinical trials
Relationship between type of therapeutic intervention and funding source in randomized clinical trials (RCTs) in oncology
The clinical trial assessment of infrastructure matrix tool (CT AIM) to improve the quality of research conduct in the community
The road to assessing clinical trial-associated workload
Which formats for communicating patient-reported outcomes (PROs) work best?